MAY 21, 2019 11:48 PM PDT

New Viable Drug Target for Prostate Cancer

WRITTEN BY: Nouran Amin

In the research community, MYC is historically known to be a difficult oncogene to target in cancer therapy. However, a recent study in the Journal of Cell Biology has found that an enzyme called PHLPP2 can serve as a potential route to target the MYC gene.

Histology slide of prostate cancer showing both benign glands and prostate carcinoma. Credit: Oncolex.org

"Now, we have a new way of getting at this old foe in cancer research," said Cold Spring Harbor Laboratory (CSHL) researcher Lloyd Trotman, who was focused on a cure for prostate cancer--one of the most prevalent cancers among men and the second leading cause of cancer death in American men.

Prostate cancer can metastasize to other parts of the body and patients with metastatic cancer have a much-reduced rate of survival than if the cancer was contained in the organ.

Now the study, co-led by Dr. Trotman and Dr. Dawid Nowak, an assistant professor at Weill Cornell and a former postdoctoral fellow at the Trotman lab, was able to examine the natural process of prostate cancer metastasis in mice and how to halt these processes by deleting the PHLPP2 enzyme.

The PHLPP2 enzyme is a critical protein in a signal pathway implicated in cell growth and survival in response to extracellular communications and signal relays. For prostate cancer, PHLPP2 cause the progression and later metastasis because it stabilizes and supports the MYC oncogene. Thus, blocking PHLPP2 can be proven as a viable drug target for the treatment of prostate cancer as it can halt the progression of cancer growth and metastasis. In addition, deleting the enzyme didn't show any symptoms of toxicity in mice or human cells.

Source: Cold Spring Harbor Laboratory

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 15, 2020
Immunology
APR 15, 2020
Does COVID-19 Attack the Immune System like HIV?
Researchers from the US and China have found that COVID-19 can destroy T cells, a type of lymphocyte that plays a key ro ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 14, 2020
Immunology
MAY 14, 2020
Antibody-laden Nanoparticles to Help COVID Patients Breathe Easy
Antibodies are a powerful countermeasure against COVID-19. Not only can they relieve symptoms in patients experiencing s ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Fecal Transplant Helps Fight off Antibiotic Resistance
Fecal transplants work by transporting fecal matter from healthy donors to those who are less healthy. Now, a study has ...
MAY 23, 2020
Cancer
MAY 23, 2020
A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis
Breast cancer, one of the most common cancers in the world, are commonly separated into one of several sub-types. These ...
MAY 10, 2020
Drug Discovery & Development
MAY 10, 2020
Antiviral Drug Treats Naso-Pharyngeal Cancer
Scientists at Hong Kong Baptist University (HKBU) developed a novel anti-Epstein-Barr virus (EBV) drug that can shrink t ...
Loading Comments...